Welcome to our dedicated page for Century Therapeutics SEC filings (Ticker: IPSC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Century Therapeutics, Inc. (NASDAQ: IPSC) SEC filings page on Stock Titan provides access to the company’s official U.S. regulatory documents, including Forms 10-K, 10-Q, 8-K and other submissions. These filings offer detailed information on Century Therapeutics’ iPSC-derived cell therapy pipeline, financial position and material corporate events.
Century Therapeutics uses its SEC reports to describe its focus on autoimmune diseases, cancer and Type 1 diabetes, its Allo-Evasion™ immune evasion technology, and programs such as CNTY-101, CNTY-308 and CNTY-813. Current reports on Form 8-K have disclosed items like private placement financing arrangements, Nasdaq listing status developments, workforce reductions, board and executive changes, and earnings press releases.
Through periodic filings such as Forms 10-Q and 10-K, investors can review Century Therapeutics’ reported cash, cash equivalents and investments, research and development and general and administrative expenses, collaboration revenue recognition and accumulated deficit. Risk factor and business sections in these reports provide the company’s own discussion of uncertainties related to clinical development, regulatory approvals, collaborations and market conditions.
Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand the implications of new documents. Real-time updates from EDGAR ensure that new IPSC filings, including 8-Ks on material events and any Form 4 insider transaction reports, are added as they become available. Use this page to navigate directly to the filings most relevant to your analysis of Century Therapeutics’ business, pipeline and capital structure.
Century Therapeutics SVP Finance & Operations Douglas Carr reported an automatic sale of common stock tied to tax withholding on vested restricted stock units. On March 9, 2026, he sold 247 shares at $2.536 per share to cover tax obligations. After this transaction, he continued to hold 514,304 shares of Century Therapeutics common stock directly. The footnote explains these sales were required and not at his discretion, indicating a routine tax-related transaction rather than an active portfolio decision.
Century Therapeutics, Inc. President and CEO Brent Pfeiffenberger reported a tax-related share disposition. On the vesting of restricted stock units, 463 shares of common stock were withheld by the company at $2.56 per share to satisfy tax withholding obligations. This was not an open-market sale. After this withholding, he directly holds 3,766,355 shares of Century Therapeutics common stock.
Century Therapeutics, Inc. President and CEO Brent Pfeiffenberger reported a tax-related share disposition. On February 13, 2026, 31,172 shares of common stock were withheld by the company at $1.75 per share to satisfy tax obligations tied to restricted stock unit vesting. After this withholding, he directly owned 3,766,818 common shares.
Century Therapeutics, Inc. (IPSC) received an updated ownership filing showing that Point72 entities report beneficial ownership of 5,961,563 common shares, representing 6.8% of the company. The stake is held through Point72 Associates, LLC, with Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen reporting shared voting and investment power.
The information is stated as of the close of business on January 2, 2026 and is filed as Amendment No. 1 to correct beneficial ownership previously disclosed. The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Century Therapeutics.
Century Therapeutics SVP Finance & Operations Douglas Carr reported a small automatic share sale linked to equity compensation. On February 3, 2026, he sold 323 shares of Common Stock at $1.822 per share to cover tax withholding obligations from vesting restricted stock units.
After this tax-related sale, Carr beneficially owned 514,551 shares of Century Therapeutics common stock, held directly. The filing explains that the transaction was executed automatically and was not made at his discretion.
Century Therapeutics, Inc. is registering 176,086,947 shares of common stock for resale by existing investors following a January 7, 2026 private placement. The shares include PIPE stock plus shares issuable from pre-funded and common warrants.
This is a secondary offering, so Century will not receive proceeds from any stockholder sales, though it may receive cash if warrants are exercised. Century develops off‑the‑shelf iPSC-derived cell therapies for autoimmune diseases and cancer, with lead programs CNTY‑813 for Type 1 diabetes, CNTY‑308 for B‑cell diseases, and CNTY‑101 for B‑cell‑mediated autoimmune diseases.
Century Therapeutics President and CEO Brent Pfeiffenberger received new equity awards. On February 2, 2026, he was granted 475,000 shares of common stock in the form of restricted stock units at a price of $0 per share.
He also received a stock option for 945,000 shares of common stock at an exercise price of $1.84 per share. The RSUs vest 25% on February 2, 2027, with the remaining 75% vesting quarterly over three years, while the option vests 25% on February 2, 2027 and the rest in 36 equal monthly installments, all subject to continued service.
Century Therapeutics, Inc. reported that Chief Technology and Manufacturing Officer Gregory Russotti received new equity awards. On February 2, 2026, he was granted 135,000 shares of common stock in the form of restricted stock units at $0 per share, increasing his directly held common stock to 525,982 shares. The RSUs vest 25% on February 2, 2027, with the remaining 75% vesting quarterly over the following three years, subject to his continued service.
Russotti was also granted a stock option for 265,000 shares of common stock at an exercise price of $1.84 per share, vesting 25% on February 2, 2027 and the balance in 36 equal monthly installments thereafter. In addition, 92,773 shares of common stock are reported as indirectly owned through the Gregory Russotti 2021 Family Trust.
Century Therapeutics Chief Scientific Officer Chad Cowan received new equity awards in the form of restricted stock units and stock options. On February 2, 2026, he was granted 135,000 restricted stock units at no cash cost, increasing his directly held common stock to 1,178,476 shares. The RSUs vest 25% on February 2, 2027, with the remaining 75% vesting quarterly over the following three years, subject to his continued service. He was also granted a stock option covering 265,000 shares of common stock at an exercise price of $1.84 per share, vesting 25% on February 2, 2027 and the balance in 36 equal monthly installments, also subject to continued service. Separately, 10,697 shares are held indirectly by the Cowan Investment Nominee Trust, for which he disclaims beneficial ownership except for any pecuniary interest.